Literature DB >> 20078321

Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer.

G Clemente1, C Chiarla, I Giovannini, A M De Rose, A Astone, C Barone, G Nuzzo.   

Abstract

OBJECTIVES: Acute abdominal symptoms with CT scan evidence of intramural gas in bowel walls (pneumatosis cystoides intestinalis, PCI) and of gas in the portal venous blood (PBG) in patients undergoing chemotherapy may represent a worrisome picture, suggestive of bowel necrosis. This picture remains a major clinical clue and the reporting of new cases may help to share awareness and experience on management. We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction.
METHODS: After admission for mucositis with diarrhea and profound dehydration, and subsequent emergency laparotomy for derotation of an intestinal volvulus, on the tenth postoperative day the patient developed fever and abdominal pain, with CT scan evidence of PCI with PBG. The exam of the abdomen did not suggest major problems requiring emergency surgery, and antibiotic treatment with close monitoring were performed, followed by rapid improvement.
RESULTS: Twelve days later, after resumption of oral diet, the patient unexpectedly suffered a spontaneous jejunal microperforation, requiring emergency laparotomy and bowel resection. Pathology showed that the perforation was within an area of ulceration involving the inner superficial layer of the bowel. Subsequently recovery was normal and at present, after 15 months, the patient is well and continuing chemotherapy.
CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation. It provides an example of the challenges involved in the management of this type of patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20078321     DOI: 10.1185/03007990903566798

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Pneumatosis cystoides intestinalis.

Authors:  Francesco Azzaroli; Laura Turco; Liza Ceroni; Stefania Sartoni Galloni; Federica Buonfiglioli; Claudio Calvanese; Giuseppe Mazzella
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 2.  Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.

Authors:  Akihito Fujimi; Hiroki Sakamoto; Yuji Kanisawa; Shinya Minami; Yasuhiro Nagamachi; Naofumi Yamauchi; Soushi Ibata; Junji Kato
Journal:  Clin J Gastroenterol       Date:  2016-09-16

3.  Two Cases of Pneumatosis Intestinalis during Cetuximab Therapy for Advanced Head and Neck Cancer.

Authors:  James A Miller; Daniel J Ford; Mohamed S Ahmed; Thom R Loree
Journal:  Case Rep Oncol Med       Date:  2015-07-29

4.  Pneumatosis cystoides intestinalis after cetuximab chemotherapy for squamous cell carcinoma of parotid gland.

Authors:  Christos Petrides; Neofytou Kyriakos; Ioannou Andreas; Parpounas Konstantinos; Georgiou Chrysanthos; Petrou Athanasios; Emmanouil Pikoulis
Journal:  Case Rep Surg       Date:  2015-01-31

Review 5.  Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.

Authors:  Kun Zou; Shuailong Yang; Liang Zheng; Chaogang Yang; Bin Xiong
Journal:  BMC Cancer       Date:  2016-09-15       Impact factor: 4.430

Review 6.  Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review.

Authors:  Gianluca Gazzaniga; Federica Villa; Federica Tosi; Elio Gregory Pizzutilo; Stefano Colla; Stefano D'Onghia; Giusy Di Sanza; Giulia Fornasier; Michele Gringeri; Maria Victoria Lucatelli; Giulia Mosini; Arianna Pani; Salvatore Siena; Francesco Scaglione; Andrea Sartore-Bianchi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.